Du Xuqin, Xie Chunguang, Shi Lipeng, Gao Hong, Yang Chan, Liu Qionghui
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
Clinical Department, Traditional Chinese medicine hospital Dianjiang Chongqing, Dianjiang, Chongqing, China.
Medicine (Baltimore). 2020 Mar;99(13):e19708. doi: 10.1097/MD.0000000000019708.
The prevalence of prediabetes and diabetes is increasing rapidly, and 5% to 10% of prediabetic patients will develop diabetes every year. Diabetes causes major health problems as well as a large economic burden. Human studies have demonstrated the beneficial effects of probiotics, prebiotics, and synbiotics supplementation in prediabetes. However, there are no systematic reviews that explore the therapeutic efficacy of probiotics, prebiotics, and synbiotics supplementation in patients with prediabetes. Therefore, we aim to synthesize the existing evidence evaluating the effectiveness and safety of probiotics, prebiotics, and synbiotics supplementation in prediabetic patients.
We will search PubMed, EMBASE, Cochrane Library, Web of Science, the Clinical Trials.gov website, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang Data Knowledge Service Platform from inception to August 2020. Additionally, the search will be conducted in multiple languages. Search terms are keywords and medical subject headings related to prediabetes, probiotics, prebiotics, and synbiotics. The primary outcomes are differences in glycated hemoglobin and fasting blood glucose. The secondary outcomes are differences in fasting insulin, homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index, and adverse events. The meta-analysis will be performed using the Revman5.3.0 software provided by the Cochrane Collaboration.
Our study will systematically evaluate the effectiveness and safety of probiotics, prebiotics, and synbiotics supplementation in prediabetes.
The findings of this study will provide the best available evidence for probiotics, prebiotics, and synbiotics in the treatment of prediabetes, and provide a strong basis for clinical treatment.
糖尿病前期和糖尿病的患病率正在迅速上升，每年有5%至10%的糖尿病前期患者会发展为糖尿病。糖尿病会引发重大健康问题并带来巨大经济负担。人体研究已证明补充益生菌、益生元及合生元对糖尿病前期有益。然而，尚无系统性综述探讨补充益生菌、益生元及合生元对糖尿病前期患者的治疗效果。因此，我们旨在综合现有证据，评估补充益生菌、益生元及合生元对糖尿病前期患者的有效性和安全性。
我们将检索PubMed、EMBASE、Cochrane图书馆、科学引文索引、ClinicalTrials.gov网站、中国知网、中国科技期刊数据库和万方数据知识服务平台，检索时间范围为建库至2020年8月。此外，检索将使用多种语言进行。检索词为与糖尿病前期、益生菌、益生元及合生元相关的关键词和医学主题词。主要结局指标为糖化血红蛋白和空腹血糖的差异。次要结局指标为空腹胰岛素、胰岛素抵抗稳态模型评估、定量胰岛素敏感性检查指数及不良事件的差异。将使用Cochrane协作网提供的Revman5.3.0软件进行荟萃分析。
我们的研究将系统评估补充益生菌、益生元及合生元对糖尿病前期的有效性和安全性。
本研究结果将为益生菌、益生元及合生元治疗糖尿病前期提供最佳现有证据，并为临床治疗提供有力依据。
